Erlotinib

Drug West-Ward Pharmaceuticals
Total Payments
$704,945
Transactions
6
Doctors
0
Companies
2

Payment Trends by Year

Year Amount Transactions Doctors
2018 $553,155 2 0
2017 $151,790 4 0

Payments by Nature

Nature of Payment Amount Transactions Share
Unspecified $704,945 6 100.0%

Research Studies & Clinical Trials

Study Name Sponsor Amount Doctors
Erlotinib Tablets, 100 mg, Pivotal Study West-Ward Pharmaceuticals $278,630 0
Erlotinib Tablets, 150 mg, Pivotal Study West-Ward Pharmaceuticals $274,525 0
Phase II Study Of Stereotactic Radiosurgery or Other Local Ablation Followed by Erlotinib for Patients with EGFR Mutation Who Have Previously Progressed on an EGFR-TKI Astellas Pharma Global Development $75,734 0
A phase II trial of rapid initiation of first-line erlotinib for advanced NSCLC using genotyping of cell-free plasma DNA Astellas Pharma Global Development $48,431 0
Phase-II-125 analysis of EGFR mutation status in patient plasma Astellas Pharma Global Development $27,124 0
A Phase 1 trial of low dose daily erlotinib in combination with high dose twice weekly erlotinib in patients with EGFR mutant lung cancer Astellas Pharma Global Development $500.00 0

Top Doctors Receiving Payments for Erlotinib

Doctor Specialty Location Total Records
Unknown — Sacramento, CA $704,945 6

Manufacturing Companies

Product Information

  • Type Drug
  • Total Payments $704,945
  • Total Doctors 0
  • Transactions 6

About Erlotinib

Erlotinib is a drug associated with $704,945 in payments to 0 healthcare providers, recorded across 6 transactions in the CMS Open Payments database. The primary manufacturer is West-Ward Pharmaceuticals.

Payment data is available from 2017 to 2018. In 2018, $553,155 was paid across 2 transactions to 0 doctors.

The most common payment nature for Erlotinib is "Unspecified" ($704,945, 100.0% of total).

Erlotinib is associated with 6 research studies, including "Erlotinib Tablets, 100 mg, Pivotal Study" ($278,630).